Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801258 | 0.82 | ALDH1A1 (0.37) | CHRM3OPRM1CHRM2CHRM1SLC6A2 | |
| SCHEMBL2800622 | 0.79 | LMNA (0.43) | OPRM1ALDH1A1RECQL | |
| SCHEMBL22437368 | 0.78 | TSHR (0.47) | CHRM3OPRM1CHRM2CHRM1SLC6A2 | |
| SCHEMBL19032591 | 0.78 | EPHX2 (0.40) | — | |
| SCHEMBL2376304 | 0.77 | PPM1D (0.40) | — | |
| SCHEMBL19839361 | 0.76 | TACR1 (0.37) | OPRM1SLC6A4OPRL1 | |
| SCHEMBL4900900 | 0.76 | CHRM3 (0.44) | CHRM3OPRM1CHRM2CHRM1SLC6A2 | |
| SCHEMBL26649093 | 0.76 | CHRM3 (0.44) | CHRM3OPRM1CHRM2CHRM1SLC6A2 | |
| SCHEMBL31057226 | 0.74 | LTA4H (0.51) | ALDH1A1 | |
| SCHEMBL19839325 | 0.73 | DGAT1 (0.38) | OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | BIOGEN IDEC MA INC. A CORPORATION | 2010-07-01 | — | — | US | disclosed |
| EP-1973914-A2 | TRANSFORMING GROWTH FACTOR MODULATORS | Biogen Idec MA Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007076086-A2 | TRICYCLIC SPIRO COMPOUNDS USEFUL AS TRANSFORMING GROWTH FACTOR MODULATORS | BIOGEN IDEC MA INC (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100166819-A1 | Transforming Growth Factor Modulators | ACVR1, TGFBR1, ACVRL1 | CHRM3 1030/4885OPRM1 1875/4885CHRM2 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.